Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jan 17, 2017

(R) Cantargia publishes prospectus and certain new financial information

Jan 16, 2017

(R) Extraordinary general meeting in Cantargia

Jan 5, 2017

(R) Cantargia’s research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017

Dec 20, 2016

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Dec 20, 2016

(R) Cantargia announces rights issue of approximately MSEK91

Dec 19, 2016

(R) Cantargia’s development project exposed by leading scientific journal

Dec 16, 2016

(R) Cantargia and SMS-oncology conclude agreement on implementation of clinical phase I/IIa trial

Nov 21, 2016

(R) Cantargia publishes interim report for January – September 2016

Nov 3, 2016

(R) Studies using Cantargia's antibodies in models of chronic myeloid leukaemia presented at the American Society of Hematology

Oct 24, 2016

(R) Cantargia raises MSEK 24.6 through exercise of warrants

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye